Article (Scientific journals)
Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review.
Efficace, Fabio; Cannella, Laura; Sparano, Francesco et al.
2022In HemaSphere, 6 (12), p. 802
Peer Reviewed verified by ORBi
 

Files


Full Text
hs9-6-e802.pdf
Author postprint (885.66 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] The inclusion of patient-reported outcome (PRO) measures in chimeric antigen receptor (CAR) T-cell therapy research is critical for understanding the impact of this novel approach from a unique patient standpoint. We performed a scoping review to map the available literature on the use of PRO measures in CAR T-cell therapy studies of patients with hematologic malignancies published between January 2015 and July 2022. Fourteen studies were identified, of which 7 (50%) were investigational early-phase trials, 6 (42.9%) were observational studies, and 1 (7.1%) was a pilot study. The EQ-5D and the PROMIS-29 were the 2 most frequently used PRO measures, being included in 6 (42.9%) and 5 (35.7%) studies, respectively. Despite differences in study designs, there seems to be evidence of improvements over time since CAR T-cell infusion in important domains such as physical functioning and fatigue, at least in patients who respond to therapy. Overall, the studies identified in our review have shown the added value of PRO assessment in CAR T-cell therapy research by providing novel information that complements the knowledge on safety and efficacy. However, there are several questions which remain to be answered in future research. For example, limited evidence exists regarding patient experience during important phases of the disease trajectory as only 4 (28.6%) and 5 (35.7%) studies provided information on PROs during the first 2 weeks from CAR T-cell infusion and after the first year, respectively. Time is ripe for a more systematic implementation of high-quality PRO assessment in future clinical trials and in real-life settings of patients treated with CAR T-cell therapy.
Disciplines :
Hematology
Author, co-author :
Efficace, Fabio;  Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health
Cannella, Laura;  Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health
Sparano, Francesco;  Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health
Giesinger, Johannes M;  University Hospital of Psychiatry II, Medical University of Innsbruck, Austria.
Vignetti, Marco;  Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health
Baron, Frédéric  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service d'hématologie clinique ; Université de Liège - ULiège > GIGA > GIGA I3 - Hematology
Bruera, Eduardo;  Palliative Care & Rehabilitation Medicine, UT M. D. Anderson Cancer Center,
Luppi, Mario;  Section of Hematology, Department of Medical and Surgical Sciences, University of
Platzbecker, Uwe;  Department of Hematology and Cellular Therapy, Medical Clinic and Policlinic I,
Language :
English
Title :
Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review.
Publication date :
December 2022
Journal title :
HemaSphere
eISSN :
2572-9241
Publisher :
Wolters Kluwer, Us
Volume :
6
Issue :
12
Pages :
e802
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.
Available on ORBi :
since 29 December 2022

Statistics


Number of views
55 (2 by ULiège)
Number of downloads
34 (1 by ULiège)

Scopus citations®
 
6
Scopus citations®
without self-citations
6
OpenCitations
 
0

Bibliography


Similar publications



Contact ORBi